<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504606</url>
  </required_header>
  <id_info>
    <org_study_id>HU-009-01</org_study_id>
    <nct_id>NCT02504606</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial was evaluated to compare the safety and pharmacokinetics of Besylsartan
      with Amosartan, which was available commercially after single oral dose in healthy male
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in blood concentration of Amlodipine</measure>
    <time_frame>144 hour</time_frame>
    <description>Detect the change of blood concentration of Amlodipine by LC-MS/MS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in blood concentration of Losartan</measure>
    <time_frame>10 hour</time_frame>
    <description>Detect the change of blood concentration of Losartan by LC-MS/MS</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Besylsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amlodipine besylate 6.944mg+losartan K 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amosartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amlodipine besylate 7.841mg+losartan K 100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besylsartan</intervention_name>
    <description>Amlodipin besylate 6.944mg+Losartan K 100mg</description>
    <arm_group_label>Besylsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amosartan</intervention_name>
    <description>Amlodipin besylate 7.841mg+Losartan K 100mg</description>
    <arm_group_label>Amosartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) between 18 and 30

          -  Healthy as determined by a responsible physician

        Exclusion Criteria:

          -  History of clinically significant disease

          -  Any chronic disease

          -  Creatine clearance less than 50ml/min

          -  Hypotension (100mmHg/60mmHg)

          -  Treatment of barbital type drug within 1 month

          -  Administration of herbal medicine within 7 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

